Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...
Eli Lilly’s profit doubled in the fourth quarter ... Revenue from the breast cancer treatment Verzenio also helped in the fourth quarter, climbing 36% to $1.55 billion. Overall, Lilly’s ...
Hosted on MSN1d
LLY Rises More Than 4% in a Week: How to Play the StockEli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...
Eli Lilly's existing portfolio, excluding incretins, also has potential growth contributors. The pharmaceutical company is expected to benefit from blockbuster products like Verzenio in oncology, ...
It is tailored to patients being treated with Lilly's oncology drugs – which include blockbuster CDK 4/ 6 inhibitor Verzenio (abemaciclib) for hormone receptor-positive, HER2-negative breast ...
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals ...
Sales of Lilly’s incretin medicines, Mounjaro, Trulicity and Zepbound, missed estimates, while that of non-incretin drugs like Jardiance, Taltz and Verzenio beat expectations. Lilly’s non ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback